<International Circulation>: Clinical experience from studies shows that aliskerin， alone or in combination with other antihypertensive therapies， provides effective blood pressure lowering with good safety and tolerability profiles. How should we use direct renin inhibitors (DRIs) among different populations such as hypertensives， nephrology patients or diabetic nephrology patients?

 《国际循环》：临床研究经验表明aliskerin独立或联合其它抗高血压药物治疗可有效地降低血压，具有安全和耐受性高的特点。我们应该如何在不同的人群如高血压，肾脏病或糖尿病肾病患者中使用直接肾素抑制剂（DRIs）？

    Prof. Whaley-Connell:We think of aliskerin， which is a direct renin inhibitor， as a global strategy in inhibiting the renin-angiotensin-aldosterone system. Right now， there is some very promising clinical data with regards to aliskerin and targeting proteinuria as a potential for risk modification for kidney disease patients and in patients that have cardiovascular disease. However， right now， the data is a little bit limiting in comparing it to ACEs or ARBs and largely where it has fallen in clinical practice is that it is largely very similar in efficacy to other ACEs and ARBs and can be used interchangeably. 

    Dr Whaley-Connell:我们认为aliskerin是一种直接肾素抑制剂，是抑制肾素血管紧张素醛固酮系统的一个全球策略。目前，关于aliskerin和将蛋白尿作为肾脏疾病和心血管疾病患者一个有效的风险修正因子的研究获得了一些非常有意义的临床数据。但与ACEs或ARBs相比，这些数据有一些局限，主要是因为aliskerin与其它ACEs或ARBs的药效非常相似且互相可以替换使用，限制了aliskerin的临床使用。